June 16 (Reuters) - Aurinia Pharmaceuticals Inc AUP.TO :
* Voclosporin remission data from the phase IIB aura-LV study highlighted at eular 2017
* Aurinia Pharmaceuticals Inc - no unexpected safety signals nor adverse events were observed and voclosporin was generally well-tolerated
* Aurinia Pharmaceuticals - there were no electrolyte changes in treatment groups, mean blood pressure was similar across treatment groups through 48 weeks
* Aurinia Pharmaceuticals - voclosporin treated groups showed statistically significant improvement over control group in speed, rates of complete, partial remission
* Aurinia Pharma- voclosporin treated groups demonstrated statistically significant improvement over control group in speed, rates of complete, partial remission Source text for Eikon: ID:nBwbSVbMLa Further company coverage: AUP.TO